Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference

April 8, 2026 at 7:01 AM EDT

DURHAM, N.C.--(BUSINESS WIRE)--Apr. 8, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop *in vivo* gene editing therapies for high unmet need diseases, today announced the Company will participate in the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026.

25th Annual Needham Virtual Healthcare Conference
Format: Virtual Corporate presentation
Date/Time: Tuesday, April 14, 2026 at 9:30am ET
Webcast Link: Precision BioSciences Virtual Presentation Link

If you are interested in meeting with the Precision team during the conference, please reach out to your Needham representative.

A replay of the presentation will be available on the Company's website in the Investors section under Events and Presentations following the event.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases to drive more defined therapeutic outcomes. Using ARCUS, the Company's pipeline is comprised of clinical stage *in vivo* gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

The ARCUS® platform is being used to develop *in vivo* gene editing therapies for sophisticated gene edits, including gene elimination (removing a genome e.g. viral DNA such as in the Company's PBGENE-HBV program), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV such as in the Company's PBGENE-DMD program) and gene insertion (inserting DNA into gene to cause expression/add function).

View source version on businesswire.com: https://www.businesswire.com/news/home/20260408018177/en/

Investor and Media Contact:
Naresh Tanna
Vice President of Investor Relations
naresh.tanna@precisionbiosciences.com

Source: Precision BioSciences, Inc.